Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

ReGenX grants AveXis global rights to use rAAV9 vectors in SMA therapies; deal expanded

Executive Summary

ReGenX Biosciences LLC granted fellow gene therapy firm AveXis Inc. exclusive worldwide rights--plus sublicensing rights--to use its NAV-based recombinant adeno-associated virus rh9 (rAAV9) vectors to develop treatments for spinal muscular atrophy (SMA).
Deal Industry
  • Biotechnology
    • Gene Therapy, Cell Therapy
    • Large Molecule
  • Pharmaceuticals
    • Drug Delivery
      • Macromolecule
Deal Status
  • Final
Deal Type
  • Alliance
    • Includes Contract
    • R+D and Marketing-Licensing
    • Intra-Biotech Deal

Related Companies